Objective
To evaluate the relation between diagnosis of covid-19 with SARS-CoV-2 variant B.1.1.7 (also known as variant of concern 202012/01) and the risk of hospital admission compared with diagnosis with wild-type SARS-CoV-2 variants.
Design
Retrospective cohort analysis.
Setting
Community based SARS-CoV-2 testing in England, individually linked with hospital admission data.
Participants
839 278 patients with laboratory confirmed covid-19, of whom 36 233 had been admitted to hospital within 14 days, tested between 23 November 2020 and 31 January 2021 and analysed at a laboratory with an available TaqPath assay that enables assessment of S-gene target failure (SGTF), a proxy test for the B.1.1.7 variant. Patient data were stratified by age, sex, ethnicity, deprivation, region of residence, and date of positive test.
Main outcome measures
Hospital admission between one and 14 days after the first positive SARS-CoV-2 test.
Results
27 710 (4.7%) of 592 409 patients with SGTF variants and 8523 (3.5%) of 246 869 patients without SGTF variants had been admitted to hospital within one to 14 days. The stratum adjusted hazard ratio of hospital admission was 1.52 (95% confidence interval 1.47 to 1.57) for patients with covid-19 infected with SGTF variants, compared with those infected with non-SGTF variants. The effect was modified by age (P<0.001), with hazard ratios of 0.93-1.21 in patients younger than 20 years with versus without SGTF variants, 1.29 in those aged 20-29, and 1.45-1.65 in those aged ≥30 years. The adjusted absolute risk of hospital admission within 14 days was 4.7% (95% confidence interval 4.6% to 4.7%) for patients with SGTF variants and 3.5% (3.4% to 3.5%) for those with non-SGTF variants.
Conclusions
The results suggest that the risk of hospital admission is higher for people infected with the B.1.1.7 variant compared with wild-type SARS-CoV-2, likely reflecting a more severe disease. The higher severity may be specific to adults older than 30 years.
The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK’s first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates, and find a four-fold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission, as well as the burden of COVID-19 disease.
Researchers are often challenged with assessing the impact of an intervention on an outcome of interest in situations where the intervention is non-randomised, the intervention is only applied to one or few units, the intervention is binary, and outcome measurements are available at multiple time points. In this paper, we review existing methods for causal inference in these situations. We detail the assumptions underlying each method, emphasize connections between the different approaches and provide guidelines regarding their practical implementation. Several open problems are identified thus highlighting the need for future research.
A problem that is frequently encountered in many areas of scientific research is that of estimating the effect of a non-randomized binary intervention on an outcome of interest by using time series data on units that received the intervention ('treated') and units that did not ('controls'). One popular estimation method in this setting is based on the factor analysis (FA) model. The FA model is fitted to the preintervention outcome data on treated units and all the outcome data on control units, and the counterfactual treatment-free post-intervention outcomes of the former are predicted from the fitted model. Intervention effects are estimated as the observed outcomes minus these predicted counterfactual outcomes. We propose a model that extends the FA model for estimating intervention effects by jointly modelling the multiple outcomes to exploit shared variability, and assuming an auto-regressive structure on factors to account for temporal correlations in the outcome. Using simulation studies, we show that the method proposed can improve the precision of the intervention effect estimates and achieve better control of the type I error rate (compared with the FA model), especially when either the number of preintervention measurements or the number of control units is small. We apply our method to estimate the effect of stricter alcohol licensing policies on alcohol-related harms.
Understanding the trajectory of the daily numbers of deaths in people with CoVID-19 is essential to decisions on the response to the CoVID-19 pandemic. Estimating this trajectory from data on numbers of deaths is complicated by the delay between deaths occurring and their being reported to the authorities. In England, Public Health England receives death reports from a number of sources and the reporting delay is typically several days, but can be several weeks. Delayed reporting results in considerable uncertainty about the number of deaths that occurred on the most recent days. In this article, we estimate the number of deaths per day in each of five age strata within seven English regions. We use a Bayesian hierarchical model that involves a submodel for the number of deaths per day and a submodel for the reporting delay distribution. This model accounts for reporting-day effects and longer-term changes over time in the delay distribution. We show how the model can be fitted in a computationally efficient way when the delay distribution is same in multiple strata, e.g. over a wide range of ages.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.